Kallyope Inc. is a biotech company located in New York, NY 10016[2]. The company develops medicines based on insights into neural signaling pathways, with a focus on the gut-brain axis[1]. Kallyope's therapeutic approach targets migraine treatment[1], with Elismetrep serving as its lead asset[1].
Something wrong or missing? Send a correction. Fixed within 24 hours.